-

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.

Contacts

Investor: investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$XBI
Hashtags
#AI
#BioStrand
#Omics
#antibodydiscovery
#bioinformatics
#biotechnology
#biotherapeutics
#covid19
#drugdiscovery
#futurepandemic
#omics
#personalizedmedicine
#polytope
#precisionmedicine
#variants

Contacts

Investor: investors@ipatherapeutics.com

Social Media Profiles
Facebook
Linkedin
Substack
Twitter
YouTube
More News From ImmunoPrecise Antibodies

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year r...

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions mor...

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session....
Back to Newsroom